Table 2.
Clinical trials.
| Category | Interventions | Clinical trial ID |
|---|---|---|
| anti-CTLA-4 | Ipilimumab (anti-CTLA-4) + Gemcitabine | NCT01473940 |
| anti-CTLA-4/ anti-PD- | Tremelimumab (anti-CTLA-4) + Durvalumab (anti-PD-L1) | NCT02527434 |
| Ipilimumab (anti-CTLA-4) or Nivolumab (anti-PD-1) + VX15/2503 (anti-SEMA4D antibody) | NCT03373188 | |
| Niraparib (PARP inhibitor) + Nivolumab (anti-PD-1) or Ipilimumab (anti-CTLA-4) | NCT03404960 | |
| anti-PD-1/ PD-L1 | Pembrolizumab (anti-PD-1) + ACP-196 | NCT02362048 |
| Pembrolizumab (anti-PD-1) + Vaccinia virus (p53 vector) | NCT02432963 | |
| Nivolumab (anti-PD-1) + Cabiralizumab (anti-CSF-1R) | NCT02526017 | |
| Pembrolizumab (anti-PD-1) + AMG820 (anti-CSF-1R) | NCT02713529 | |
| Durvalumab (anti-PD-L1) + Galunisertib (TGFbeta inhibitor) | NCT02734160 | |
| Nivolumab (anti-PD-1) + Paricalcitol (Vitamin D analog) + Chemotherapies | NCT02754726 | |
| Pembrolizumab (anti-PD-1) + BL-8040 (CXCR4 antagonist) | NCT02826486 | |
| Pembrolizumab (anti-PD-1) + BL-8040 (CXCR4 antagonist) | NCT02907099 | |
| Nivolumab (anti-PD-1) + IRE | NCT03080974 | |
| Pembrolizumab (anti-PD-1) + XL888 (hsp90 inhibitor) | NCT03095781 | |
| Nivolumab (anti-PD-1) + Daratumumab (anti-CD38) | NCT03098550 | |
| Pembrolizumab (anti-PD-1) + Olaptesed (anti-CXCL12) | NCT03168139 | |
| Atezalizumab (anti-PD-L1) + BL-8040 (CXCR4 antagonist) + RO6874281 (anti-FAP) + Chemotherapies | NCT03193190 | |
| Nivolumab (anti-PD-1)+ APX005M (CD40 agonist) + Gemcitabine and Nab-Paclitaxel | NCT03214250 | |
| Durvalumab (anti-PD-L1) + Stereoactive Ablative Body Radiotherapy | NCT03245541 | |
| Nivolumab (anti-PD-1) + Entinostat (HDAC inhibitor) | NCT03250273 | |
| Durvalumab (anti-PD-L1) + Guadecitabine (DNA methyltransferase inhibitor) | NCT03257761 | |
| Pembrolizumab (anti-PD-1) + Paricalcitol (Vitamin D analog) | NCT03331562 | |
| Durvalumab (anti-PD-L1) + Radiation Therapy | NCT03490760 | |
| Nivolumab (anti-PD-1) + BMS-813160 (CCR2/CCR5 antagonist) + chemotherapies | NCT03496662 | |
| Oleclumab (anti-CD73) + Durvalumab (anti-PD-L1) + chemotherapies | NCT03611556 | |
| Pembrolizumab (anti-PD-1) + PEGPH20 (pegylated hyaluronidase) | NCT03634332 | |
| Pembrolizumab (anti-PD-1) + Pelareorep (Oncolytic Reovirus) | NCT03723915 | |
| Pembrolizumab (anti-PD-1) + Defactinib (FAK inhibitor) | NCT03727880 | |
| anti-PD-1/ vaccine | GVAX Vaccine (With CY) and CRS-207 Vaccine + Nivolumab (anti-PD-1) | NCT02243371 |
| Nivolumab (anti-PD-1) + GVAX Vaccine + Urelumab (anti-CD137) + Cyclophosphamide | NCT02451982 | |
| Peptide Vaccine + Pembrolizumab (anti-PD-1) | NCT02600949 | |
| GVAX Vaccine + Pembrolizumab (anti-PD-1) + Cyclophosphamide + SBRT | NCT02648282 | |
| Epacadostat (anti-IDO)+ Pembrolizmuab (anti-PD-1) + GVAX vaccine + CRS-207 vaccine | NCT03006302 | |
| Pembrolizumab (anti-PD-1), GVAX vaccine, IMC-CS4 (anti-CSF-1R) | NCT03153410 | |
| Nivolumab (anti-PD-1) + GVAX vaccine + SBRT + Cyclophosphamide | NCT03161379 | |
| GVAX Vaccine (With CY) and CRS-207 Vaccine + Nivolumab (anti-PD-1) + Ipilimumab (anti-CTLA4) | NCT03190265 | |
| Durvalumab (anti-PD-L1) + anti-CEA- & MUC1-vaccine | NCT03376659 | |
| GVAX Vaccine + Nivolumab (anti-PD-1) and BMS-813160 (CCR2/CCR5 antagonist) | NCT03767582 | |
| Vaccine | Allogenic GM-CSF plasmid- transfected tumor cell vaccine | NCT00389610 |
| Falimarev (anti-CEA vaccine) + Inalimarev (anti-CEA and MUC1 vaccine) + Sargramostim (recombinant GM-CSF) | NCT00669734 | |
| GVAX vaccine + Cyclophosphamide | NCT00727441 | |
| GVAX vaccine + Cyclophosphamide + SBRT + FOLFIRINOX | NCT01595321 | |
| NPC-1C vaccine + Gemcitabine + Nab-Paclitaxel | NCT01834235 | |
| Tumor derived gp96 vaccine | NCT02133079 | |
| anti-DC1 vaccine + Interferon alpha-2b + Rintatolimod (immunomodulatory RNA drug) | NCT02151448 | |
| ETBX-011 Vaccine + ALT-803 (IL-15 complex) | NCT03127098 | |
| ETBX-011 Vaccine + ALT-803 (IL-15 complex) | NCT03329248 | |
| MDC3/8 (dendritic cell KRAS vaccine) | NCT03592888 | |
| CAR-T cell therapy | Meso CAR T Cells | NCT01897415 |
| anti-CEA CAR-T cells + Sir-Spheres | NCT02416466 | |
| BPX-601 (anti PSCA CAR-T cells) + Rimiducid | NCT02744287 | |
| anti-CEA CAR-T cells | NCT02850536 | |
| antiCLD18 CAR-T cell | NCT03159819 | |
| anti-Meso CAR-T cells | NCT03323944 | |
| anti-Meso CAR-T cell vs anti-CD19 CAR-T cells + Cyclophosphamide | NCT03497819 | |
| Other T cell therapy | FOLFOX6 + Anti-Erbitux Activated T cells | NCT01420874 |
| Bispecific Antibody T cells + Aldesleukin (recombinant IL-2) + Sargramostim (recombinant GM-CSF) + chemotherapies | NCT02620865 | |
| Gemcitabine with CD8+NKG2D+ AKT cells | NCT02929797 | |
| Oncolytic virus | VCN-01 (Oncolytic Adenovirus) | NCT02045602 |
| LOAd703 (Oncolytic Adenovirus) | NCT03225989 | |
| CAdVEC Oncolytic Adenovirus | NCT03740256 | |
| Other | CD40 agonist monocolonal antibody + Gemcitabine | NCT00711191 |
| Indoximod (IDO inhibitor) + Nab-Paclitaxel + Gemcitabine | NCT02077881 | |
| TG01 injection + Gemcitabine | NCT02261714 | |
| CCX872-B (CCR2 antagonist) | NCT02345408 | |
| ALT-803 (IL-15 complex) + Gemcitabine + Nab-paclitaxel | NCT02559674 | |
| Ibrutinib (BTK inhibitor) + paclitaxel and gemcitiabine | NCT02562898 | |
| Ibrutinib (BTK inhibitor) | NCT02575300 | |
| Plerixafor (CXCR4 antagonist) | NCT03277209 | |
| CDX-1140 (anti-CD40) + CDX-301 (anti-flt3L) | NCT03329950 |
SBRT, stereotactic body radiation therapy; IRE, irreversible electroporesis; CSF-1R, colony-stimulating factor-1 receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor.